School of Medical, Kermanshah University of Medical Sciences, Kermanshah, Iran; Clinical Research Development Center, Imam Khomeini and Mohammad Kermanshahi and Farabi Hospitals, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Research Center for Environmental Determinants of Health (RCEDH), Health Inestitue, Kermanshah University of Medical Sciences, Kermanshah, Iran.
J Chromatogr B Analyt Technol Biomed Life Sci. 2021 May 1;1171:122628. doi: 10.1016/j.jchromb.2021.122628. Epub 2021 Mar 6.
Methotrexate, as a folate antagonist, is one of the first anti-neoplasm drugs offered and is still used as an effective drug in the treatment of various malignancies. Methotrexate has a narrow treatment index and is associated with numerous side effects.In thisresearch, for the first time a double-solvent supramolecular system (DSS) was developed as an extractant without disperser solvent for dispersive liquid-liquid microextraction (DLLME). DSS - DLLME was applied to the extraction of methotrexate in plasma of children with acute leukemiaprior to itsdetermination by high-performance liquid chromatography-ultraviolet detection (HPLC - UV). In the present method, two long normal chain alcohols are mixed in a particular ratio, and then it is injected into the sample solution, which is on the magnetic stirrer. In this case, the mixture of the two alcohol changes to new supramolecular aggregate. This new supermolecule is used as an extractant, which has a higher extraction power than any of its components alone. Under the optimum conditions, the calibration graph was linear in the rage of 0.1-150 µg L with detection limit of 0.03 µg L. Relative standard deviations (RSDs) including intra-day and inter-day of method based on7 replicate determinations of 100.0 µg Lof methotrexate were 2.6% and 4.8%,respectively. The results proved that DSS - DLLME is a sensitive, very simple, inexpensive, environmental friendly, rapid and efficient method for the preconcentration of trace amount of drugs in biological samples.
甲氨蝶呤作为一种叶酸拮抗剂，是最早提供的抗肿瘤药物之一，目前仍是治疗各种恶性肿瘤的有效药物。甲氨蝶呤治疗指数较窄，且有多种副作用。在本研究中，首次开发了一种双溶剂超分子体系（DSS）作为萃取剂，无需分散溶剂，用于分散液液微萃取（DLLME）。DSS-DLLME 用于在儿童急性白血病患者的血浆中萃取甲氨蝶呤，然后用高效液相色谱-紫外检测（HPLC-UV）进行测定。在本方法中，两种长链正醇以特定比例混合，然后注入到磁力搅拌的样品溶液中。在这种情况下，两种醇的混合物转变为新的超分子聚集体。这种新的超分子用作萃取剂，其萃取能力高于其任何单一成分。在最佳条件下，校准曲线在 0.1-150μg L 范围内呈线性，检测限为 0.03μg L。基于 100.0μg L 甲氨蝶呤的 7 次重复测定的日内和日间相对标准偏差（RSD）分别为 2.6%和 4.8%。结果表明，DSS-DLLME 是一种灵敏、简单、廉价、环境友好、快速高效的方法，可用于生物样品中痕量药物的预浓缩。
